Me, myself, bye: regional alterations in glutamate and the experience of ego dissolution with psilocybin

N. L. Mason, K. P. C. Kuypers, F. Müller, J. Reckweg, D. H. Y. Tse, S. W. Toennes, N. R. P. W. Hutten, J. F. A. Jansen, P. Stiers, A. Feilding & J. G. Ramaekers

Abstract

There is growing interest in the therapeutic utility of psychedelic substances, like psilocybin, for disorders characterized by distortions of the self-experience, like depression. Accumulating preclinical evidence emphasizes the role of the glutamate system in the acute action of the drug on brain and behavior; however this has never been tested in humans. Following a double-blind, placebo-controlled, parallel group design, we utilized an ultra-high field multimodal brain imaging approach and demonstrated that psilocybin (0.17 mg/kg) induced region-dependent alterations in glutamate, which predicted distortions in the subjective experience of one’s self (ego dissolution). Whereas higher levels of medial prefrontal cortical glutamate were associated with negatively experienced ego dissolution, lower levels in hippocampal glutamate were associated with positively experienced ego dissolution. Such findings provide further insights into the underlying neurobiological mechanisms of the psychedelic, as well as the baseline, state. Importantly, they may also provide a neurochemical basis for therapeutic effects as witnessed in ongoing clinical trials.

See more publications from the Beckley/Maastricht Psychedelic Programme

Psilocybin induces acute and persisting alterations in immune status in healthy volunteers: An experimental, placebo-controlled study

Brain, Behavior, and Immunity, 2023

Read more

Potential analgesic effects of psychedelics on select chronic pain conditions: A survey study

European Journal of Pain

Read more

Spontaneous and deliberate creative cognition during and after psilocybin exposure

Translational Psychiatry, 2021

Read more

Mood and cognition after administration of low LSD doses in healthy volunteers: A placebo controlled dose-effect finding study

European Neuropsychopharmacology, 2020

Read more

Pharmacokinetics and pharmacodynamics of lysergic acid diethylamide microdoses in healthy participants

Clinical Pharmacology and Therapeutics, 2020

Read more

Low Doses of LSD Acutely Increase BDNF Blood Plasma Levels in Healthy Volunteers

ACS Pharmacology & Translational Science, 2020

Read more

A low dose of lysergic acid diethylamide decreases pain perception in healthy volunteers

Journal of Psychopharmacology, 2020

Read more

Me, myself, bye: regional alterations in glutamate and the experience of ego dissolution with psilocybin

Nature – Neuropsychopharmacology, 2020

Read more